Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low absolute risk of thrombotic and cardiovascular events in outpatient pregnant women with COVID-19.
Bikdeli B, Krishnathasan D, Khairani CD, Bejjani A, Davies J, Porio N, Tristani A, Armero A, Assi AA, Nauffal V, Campia U, Almarzooq Z, Wei E, Ortiz-Rios MD, Zuluaga-Sánchez V, Achanta A, Jesudasen SJ, Tiu B, Merli GJ, Leiva O, Fanikos J, Grandone E, Sharma A, Rizzo S, Pfeferman MB, Morrison RB, Vishnevsky A, Hsia J, Nehler MR, Welker J, Bonaca MP, Carroll B, Goldhaber SZ, Lan Z, Piazza G; CORONA-VTE-Network Investigators. Bikdeli B, et al. Among authors: bonaca mp. Thromb Res. 2024 May;237:209-215. doi: 10.1016/j.thromres.2024.02.021. Epub 2024 Apr 6. Thromb Res. 2024. PMID: 38677791 Free article.
Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis.
Cavallari I, Morrow DA, Creager MA, Olin J, Bhatt DL, Steg PG, Storey RF, Cohen M, Scirica BS, Piazza G, Goodrich EL, Braunwald E, Sabatine MS, Bonaca MP. Cavallari I, et al. Among authors: bonaca mp. Circulation. 2018 Feb 13;137(7):684-692. doi: 10.1161/CIRCULATIONAHA.117.031062. Epub 2017 Oct 30. Circulation. 2018. PMID: 29084737 Clinical Trial.
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS, Berkowitz SD, Debus ES, Fanelli F, Haskell L, Patel MR, Bauersachs R, Hiatt WR. Capell WH, et al. Among authors: bonaca mp. Am Heart J. 2018 May;199:83-91. doi: 10.1016/j.ahj.2018.01.011. Epub 2018 Feb 3. Am Heart J. 2018. PMID: 29754671 Clinical Trial.
Rivaroxaban in Peripheral Artery Disease after Revascularization.
Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, Hess CN, Pap AF, Kittelson JM, Gudz I, Mátyás L, Krievins DK, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR. Bonaca MP, et al. N Engl J Med. 2020 May 21;382(21):1994-2004. doi: 10.1056/NEJMoa2000052. Epub 2020 Mar 28. N Engl J Med. 2020. PMID: 32222135 Clinical Trial.
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study.
Capell WH, Barnathan ES, Piazza G, Spyropoulos AC, Hsia J, Bull S, Lipardi C, Sugarmann C, Suh E, Rao JP, Hiatt WR, Bonaca MP. Capell WH, et al. Among authors: bonaca mp. Am Heart J. 2021 May;235:12-23. doi: 10.1016/j.ahj.2021.02.001. Epub 2021 Feb 9. Am Heart J. 2021. PMID: 33577800 Free PMC article.
Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial.
Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Sharifova G, Cohen M, Lund JM, Mignatti A, Gianos E, Tafur A, Lewis PA, Cohoon K, Kittelson JM, Lesser ML, Sison CP, Rahman H, Ochani K, Hiatt WR, Dale RA, Anderson VE, Bonaca M, Halperin JL, Weitz JI, Spyropoulos AC. Goldin M, et al. Thromb Haemost. 2021 Dec;121(12):1684-1695. doi: 10.1055/a-1475-2351. Epub 2021 May 28. Thromb Haemost. 2021. PMID: 33823560
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial.
Bauersachs RM, Szarek M, Brodmann M, Gudz I, Debus ES, Nehler MR, Anand SS, Patel MR, Hess CN, Capell WH, Rogers K, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR, Bonaca MP; VOYAGER PAD Committees and Investigators. Bauersachs RM, et al. Among authors: bonaca mp. J Am Coll Cardiol. 2021 Jul 27;78(4):317-326. doi: 10.1016/j.jacc.2021.05.003. Epub 2021 May 16. J Am Coll Cardiol. 2021. PMID: 34010631 Free article. Clinical Trial.
Supervised Exercise Therapy for Symptomatic Peripheral Artery Disease Among Medicare Beneficiaries Between 2017 and 2018: Participation Rates and Outcomes.
Divakaran S, Carroll BJ, Chen S, Shen C, Bonaca MP, Secemsky EA. Divakaran S, et al. Among authors: bonaca mp. Circ Cardiovasc Qual Outcomes. 2021 Aug;14(8):e007953. doi: 10.1161/CIRCOUTCOMES.121.007953. Epub 2021 Jul 23. Circ Cardiovasc Qual Outcomes. 2021. PMID: 34293930 Free PMC article. No abstract available.
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
Krantz MJ, Debus SE, Hsia J, Patel MR, Anand SS, Nehler MR, Hess CN, Capell WH, Bracken T, Szarek M, Mátyás L, Krievins DK, Nault P, Stefanov S, Haskell LP, Berkowitz SD, Muehlhofer E, Hiatt WR, Bauersachs RM, Bonaca MP. Krantz MJ, et al. Among authors: bonaca mp. Eur Heart J. 2021 Oct 14;42(39):4040-4048. doi: 10.1093/eurheartj/ehab408. Eur Heart J. 2021. PMID: 34430972 Clinical Trial.
262 results